Sarepta Therapeutics Inc Condensed Consolidated Statements of Operations unaudited in thousands except per share amounts For the Three Months Ended June 30 For the Six Months Ended June 30 2021 2020 2021 2020 Revenues Products net  141839  111344  266765  211792 Collaboration 22250 26019 44255 39245 Total revenues 164089 137363 311020 251037 Cost and expenses Cost of sales excluding amortization of inlicensed rights 19515 13341 41861 25963 Research and development 239622 188522 434771 324666 Selling general and administrative 72347 73688 143478 156456 Settlement and license charges   10000  Amortization of inlicensed rights 179 165 349 331 Total cost and expenses 331663 275716 630459 507416 Operating loss 167574 138353 319439 256379 Other income loss Gain from sale of Priority Review Voucher 102000  102000 108069 Other expense net 16185 12447 31713 19867 Total other income loss 85815 12447 70287 88202 Loss before income tax benefit expense 81759 150800 249152 168177 Income tax benefit expense 354 20 497 135 Net loss  81405 150820 248655 168312 Net loss per share  basic and diluted  102  193  312  218 Weighted average number of shares of common stock used in computing basic and diluted net loss per share 79746 77968 79601 77200 Sarepta Therapeutics Inc Reconciliation of GAAP Financial Measures to NonGAAP Financial Measures unaudited in thousands except per share amounts For the Three Months Ended June 30 For the Six Months Ended June 30 2021 2020 2021 2020 GAAP net loss  81405 150820 248655 168312 Interest expense net 15758 12076 31214 20588 Income tax benefit expense 354 20 497 135 Gain from sale of Priority Review Voucher 102000  102000 108069 Collaboration revenue 22250 26019 44255 39245 Depreciation and amortization expense 8447 6475 17377 13004 Stockbased compensation expense 28969 27616 57477 51640 Roche transaction costs    11292 Upfront milestone and other expenses 31677 12750 35677 21283 Settlement and license charges   10000  NonGAAP net loss 121158 117902 243662 197684 NonGAAP net loss per share Basic and diluted  152  151  306  256 Weighted average number of shares of common stock used in computing basic and diluted net loss per share 79746 77968 79601 77200 For the Three Months Ended June 30 For the Six Months Ended June 30 2021 2020 2021 2020 GAAP research and development expenses  239622  188522  434771  324666 Upfront milestone and other expenses 31677 12750 35677 21283 Stockbased compensation expense 12860 11140 23986 20389 Depreciation and amortization expense 6060 4199 12598 8376 NonGAAP research and development expenses  189025  160433  362510  274618 For the Three Months Ended June 30 For the Six Months Ended June 30 2021 2020 2021 2020 GAAP selling general and administrative expenses  72347  73688  143478  156456 Stockbased compensation expense 16109 16476 33491 31251 Depreciation and amortization expense 2208 2111 4430 4297 Roche transaction costs    11292 NonGAAP selling general and administrative expenses  54030  55101  105557  109616 Sarepta Therapeutics Inc Condensed Consolidated Balance Sheets unaudited in thousands except share and per share data As of June 30 2021 As of December 31 2020 Assets Current assets Cash and cash equivalents 1697275 1502648 Shortterm investments 30000 435923 Accounts receivable 127520 101340 Inventory 268756 231961 Other current assets 141666 213324 Total current assets 2265217 2485196 Property and equipment net 203330 190430 Intangible assets net 14105 13628 Right of use assets 72868 91761 Other noncurrent assets 203553 203703 Total assets 2759073 2984718 Liabilities and Stockholders Equity Current liabilities Accounts payable  76681  111090 Accrued expenses 240141 193553 Deferred revenue current portion 89244 89244 Other current liabilities 18956 22139 Total current liabilities 425022 416026 Longterm debt 1092985 992493 Lease liabilities net of current portion 65285 80367 Deferred revenue net of current portion 619233 663488 Contingent consideration 50800 50800 Other noncurrent liabilities 20640 19785 Total liabilities 2273965 2222959 Stockholders equity Preferred stock 00001 par value 3333333 shares authorized none issued and outstanding   Common stock 00001 par value 198000000 shares authorized 79830411 and 79374247 issued and outstanding at June 30 2021 and December 31 2020 respectively 8 8 Additional paidin capital 3521721 3609877 Accumulated other comprehensive income net of tax 2 3 Accumulated deficit 3036623  2848129  Total stockholders equity 485108 761759 Total liabilities and stockholders equity 2759073 2984718 Source Sarepta Therapeutics Inc Investor Contact Ian Estepan 6172744052 iestepansareptacom Media Contact Tracy Sorrentino 6173018566 tsorrentinosareptacom